Tohoku University Technology: Treatment for Coronavirus Disease: T20-033
A small amount of airway administration of biologically derived proteins reduces the invasion of the novel coronavirus and lung damage.
The development of preventive and early treatment drugs for COVID-19 caused by the novel coronavirus (SARS-CoV-2) is desired. This invention relates to Stanniocalcin-1 (STC1), a substance that suppresses the expression of ACE2 and TMPRSS2 (membrane proteins) necessary for the cellular entry of SARS-CoV-2. - Efficacy: In a mouse model of bleomycin-induced lung injury, STC1 was administered once via the airway, and the lungs were extracted on Day 3 and Day 14 to measure the expression levels of ACE2 and TMPRSS2. The results revealed that STC1 suppresses the expression of ACE2 and TMPRSS2 (Figure 1). Previous studies have shown that STC1 has anti-fibrotic and anti-inflammatory effects (related literature 1). In other words, STC1 can simultaneously suppress the viral intracellular entry, lung injury, and cytokine storm associated with COVID-19. - Safety: STC1 is derived from biological sources, and its administration via the airway can suppress systemic viral dissemination. Given that even a small dose of 0.1 mg/kg is effective, its safety is expected to be high. This dosage is also realistic when translated to human inhalation therapy.
- Company:Tohoku Techno Arch Co., Ltd.
- Price:Other